Search Results
14 protocol(s) meet the specified criteria
Multicenter, Phase I, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies

Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Chemotherapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study

Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CS3FR

Multicenter Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome

Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults

Dose-Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton Tyrosine Kinase Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Randomized, Phase II Study of CX-01 Combined with Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

Phase I, Multicenter, Open-Label Study of Oral ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Phase IB Study Evaluating the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination with Immunomodulatory Agents in Patients with Acute Myeloid Leukemia

Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (Remain Trial)

Phase II Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination with Ruxolitinib in Subjects with Myelofibrosis

Randomized, Double-Blind, Placebo Controlled Study of Venetoclax in Combination with Azacitidine versus Azacitidine in Treatment Naïve Elderly Subjects with Acute Myeloid Leukemia who are Ineligible for Standard Induction Therapy

Phase I, Non-Randomized, Open-Label/Phase II Randomized, Blinded Study of ProTmune versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies